// App-Quantinova.ai

P669 : Adalimumab long-term effectiveness in adalimumab-naïve patients with Crohn's disease: final data from PYRAMID registry

Researchers

Presenter

  • E. Loftus, Jr

Principal Investigators

  • G. D'Haens

  • W. Reinisch

  • J. Satsangi

  • R. Panaccione

  • S. Berg

  • G. Alperovich

  • M. Bereswill

  • J. Kalabic

  • M. Skup

  • J. Petersson

  • A.M. Robinson

Medical Centers

  • Mayo Clinic, Gastroenterology and Hepatology, Rochester, Minnesota, United States

  • Academic Medical Center, Gastroenterology & Hepatology, Amsterdam, Netherlands

  • Medical University of Vienna, Vienna, Austria

  • Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom

  • University of Calgary, Medicine, Calgary, Canada

  • AbbVie AB, Solna, Sweden

  • AbbVie Spain S.L.U., Madrid, Spain

  • AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany

  • AbbVie Inc., North Chicago, Illinois, United States

Locations

  • United States

  • Netherlands

  • Austria

  • United Kingdom

  • Canada

  • Sweden

  • Spain

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved